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Challenges for Cancer Patients Returning Home 
During COVJD-19 Pandemic after Medical Tourism - A Consensus Report 
by the Emirates Oncology Task Force 
T: e COVID-19 pandemic has caused global health crisis. Numerous ancer patients from non-Western 
countries, including the United Arab Emir· 
ates (UAE), seek cancer care outside their 
home countries and many are sponsored 
by their governments for treatment. Many 
patients interrupted their cancer treat-
ment abruptly and returned to their home 
countries with unique challenges. 
Experts from medical, surgical and other 
cancer subspecialties in the UAE were in-
vited to form a taskforce to address chal-
lenges and propose recommendations 
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for patients returning home from abroad after medical tourism during the COVID-19 pandemk. 
The taskforce looked at practical challenges and provided recommendations for cancer patients re-
turning to their countries from treatment abroad. lack of medical documentation, pathology speci-
mens and radiology images are one of the major limitations on the continuation of the cancer care for 
returning patients. Difference in approaches and treatment recommendations between the existing 
treating oncologists abroad and receiving oncologists in the UAE regarding the optimal management 
was another issue. However, this can be addressed by early and empathic communications with pa-
tients and by engaging the previous treating oncologists in treatment planning baled-on the available 
resources and expertise in the UAE. Interruption of curative radiotherapy (RT) schedules, ~hich can po-
tent ially increase the risl< of treatment fail ure, has been a major challenge. The taskforce recommend-
ed that RT dose-compensation calculation should be considered in these circumstances. 
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If you are interested in sharing your COVID-19 releated research, please send your contribution to 
research.office@uaeu.ac.ae 
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